Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma

31.07.2023 - Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte (NASDAQ:INCY), a global biopharmaceutical company, today announced a ... Seite 1

Related Keywords

Lance Leopold ,Robert Coffin ,Clinical Development Hematology ,Group Vice ,Chief Research ,Development Officer ,Incyte ,Replimune Group ,